Societal CDMO, Inc. Stock

Equities

SCTL

US75629F1093

Pharmaceuticals

Market Closed - Nyse 04:00:00 2024-04-05 pm EDT 5-day change 1st Jan Change
1.1 USD +0.92% Intraday chart for Societal CDMO, Inc. 0.00% +213.84%
Sales 2022 90.21M Sales 2023 94.64M Capitalization 36.73M
Net income 2022 -19M Net income 2023 -13M EV / Sales 2022 1.72 x
Net Debt 2022 29.21M Net Debt 2023 34.26M EV / Sales 2023 0.75 x
P/E ratio 2022
-4.34 x
P/E ratio 2023
-2.5 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 65.05%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.92%
Current month+1.85%
1 month+0.92%
3 months+214.47%
6 months+207.26%
Current year+213.84%
More quotes
1 month
1.08
Extreme 1.08
1.10
Current year
0.31
Extreme 0.3078
1.10
1 year
0.26
Extreme 0.26
1.28
3 years
0.26
Extreme 0.26
3.15
5 years
0.26
Extreme 0.26
19.21
10 years
0.26
Extreme 0.26
19.21
More quotes
Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus in the area of small molecules. It is a CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company's key products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR and Donnatal liquids and tablets. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms, with specialization in modified release technologies and facilities to handle potent compounds and controlled substances.
More about the company